# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the pri...
Latest clinical data on BB-301 treatment for OPMD. Positive results in swallowing improvement. Benitec Biopharma announces inte...
BPTH: 98% | Bio-Path Holdings shares are trading higher after the company announced the completion of its second dose cohort in...
Benitec Biopharma announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5.749 million...